The pharma company is waiting for further clarity to assess the impact of tariffs imposed by the Trump administration and the ...

Pharmazz has two late-stage pipeline drug candidates Sovateltide (for treatment of acute cerebral ischemic stroke) and ...

The company projects revenue growth of mid- to high single digits in FY26 compared with an 8.5% increase in FY25 ...

Shares of pharmaceutical giant Sun Pharma declined as much as 4.86%, hitting an intraday low of Rs 1,636.30. By 9:24 AM, the ...

Sun Pharmaceutical Industries reported a consolidated net profit of ₹2,154 crore in the fourth quarter of FY25, registering a ...

The share price of Sun Pharmaceuticals has fallen by over 4% in the last five trading sessions. The stock has fallen 6% in ...

India’s largest drugmaker plans a $100 million push into US specialty drugs in FY26, even as it braces for regulatory ...

The company also expects R&D spending to rise to 6–8% of sales, reflecting its commitment to pipeline expansion and ...

Stock continues to show pressure even with a fine tuned operating performance, US sales decline which skew profit losses.

After a legal decision delayed its entry last fall, Sun Pharma has received the all-clear to tap into the U.S. alopecia market with its JAK inhibitor Leqselvi, teeing up a potential showdown with ...

Planting seed money and “wishing” is not enough to claim “irreparable harm” to secure a preliminary injunction or to establish the standing required to appeal a patent board decision, the U.S. Court ...

The upside is due to a positive ruling by the US court regarding the launch of Leqselvi. The US Court heard arguments in the pharmaceutical company’s appeal against a previous decision by the ...